Home
Supported by an independent educational grant from Genmab US, Inc. and AbbVie Join us for a symposium on bispecific antibodies for relapsed-refractory diffuse large B-cell lymphoma designed to encourage the exchange of ideas between leaders in the field and attendees. Experts will discuss clinical trial data, adverse event management, and current treatment approaches. This program will include a dynamic panel discussion and rapid-fire Q & A as well as an interactive audience Q & A. Section Chief,